Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 169

Similar articles for PubMed (Select 24322994)


A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Ostheimer C, Bache M, Güttler A, Kotzsch M, Vordermark D.

Strahlenther Onkol. 2014 Mar;190(3):276-82. doi: 10.1007/s00066-013-0484-1. Epub 2013 Dec 11.


Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.

Ostheimer C, Bache M, Güttler A, Reese T, Vordermark D.

BMC Cancer. 2014 Nov 21;14:858. doi: 10.1186/1471-2407-14-858.


Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.

Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, Kuhnt T, Hänsgen G, Dunst J, Vordermark D.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1481-7. Epub 2006 Oct 23.


Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).

Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P.

Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):360-8. doi: 10.1016/j.ijrobp.2010.06.011. Epub 2010 Oct 1.


High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.

Ilie M, Mazure NM, Hofman V, Ammadi RE, Ortholan C, Bonnetaud C, Havet K, Venissac N, Mograbi B, Mouroux J, Pouysségur J, Hofman P.

Br J Cancer. 2010 May 25;102(11):1627-35. doi: 10.1038/sj.bjc.6605690. Epub 2010 May 11.


Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.

Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, Oosterwijk E, Kelley MJ.

Lung Cancer. 2005 Sep;49(3):325-35.


Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.

Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL.

Clin Cancer Res. 2002 Aug;8(8):2595-604.


Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.

Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR; SWOG.

J Clin Oncol. 2008 Oct 10;26(29):4771-6. doi: 10.1200/JCO.2008.17.0662. Epub 2008 Sep 8.


Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.

Simi L, Venturini G, Malentacchi F, Gelmini S, Andreani M, Janni A, Pastorekova S, Supuran CT, Pazzagli M, Orlando C.

Lung Cancer. 2006 Apr;52(1):59-66. Epub 2006 Feb 28.


Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.

Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ.

J Clin Oncol. 2003 Feb 1;21(3):473-82.


An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.

Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ.

Clin Cancer Res. 2006 Mar 1;12(5):1507-14.


Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.

Kappler M, Taubert H, Holzhausen HJ, Reddemann R, Rot S, Becker A, Kuhnt T, Dellas K, Dunst J, Vordermark D, Hänsgen G, Bache M.

Strahlenther Onkol. 2008 Aug;184(8):393-9.


Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.

Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS.

J Clin Oncol. 2010 Feb 20;28(6):936-41. doi: 10.1200/JCO.2009.25.5711. Epub 2010 Jan 19.


Carbonic anhydrase IX in early-stage non-small cell lung cancer.

Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, Vujaskovic Z, Kelley MJ.

Clin Cancer Res. 2004 Dec 1;10(23):7925-33. Erratum in: Clin Cancer Res. 2005 Apr 1;11(7):2783.


Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.

Chakra M, Pujol JL, Lamy PJ, Bozonnat MC, Quantin X, Jacot W, Daurès JP.

J Thorac Oncol. 2008 Oct;3(10):1119-26. doi: 10.1097/JTO.0b013e318187464e.


VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.

Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, Martín M, Gómez-Codina J, Montalar J, Reynés G.

Clin Transl Oncol. 2013 Nov;15(11):897-902. doi: 10.1007/s12094-013-1020-6. Epub 2013 Mar 5.


Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.

Edelman MJ, Hodgson L, Wang X, Christenson R, Jewell S, Vokes E, Kratzke R.

J Thorac Oncol. 2011 Nov;6(11):1902-6. doi: 10.1097/JTO.0b013e31822a7383.


Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma treated with radiotherapy.

Wachters JE, Schrijvers ML, Slagter-Menkema L, Mastik M, de Bock GH, Langendijk JA, Kluin PM, Schuuring E, van der Laan BF, van der Wal JE.

Laryngoscope. 2013 Sep;123(9):2154-60.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk